These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 22963436)
1. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system. Popoli P; Pepponi R CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):664-74. PubMed ID: 22963436 [TBL] [Abstract][Full Text] [Related]
2. Molecular and Structural Insight into Adenosine A Karati D; Mukherjee S; Roy S Mol Neurobiol; 2023 Oct; 60(10):5987-6000. PubMed ID: 37391647 [TBL] [Abstract][Full Text] [Related]
3. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Abbracchio MP; Cattabeni F Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415 [TBL] [Abstract][Full Text] [Related]
4. Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy. Wolska N; Rozalski M Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31684173 [TBL] [Abstract][Full Text] [Related]
7. Adenosine-stimulated adrenal steroidogenesis involves the adenosine A2A and A2B receptors and the Janus kinase 2-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase signaling pathway. Chen YC; Huang SH; Wang SM Int J Biochem Cell Biol; 2008; 40(12):2815-25. PubMed ID: 18582595 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of endogenous A Goulding J; May LT; Hill SJ Biochem Pharmacol; 2018 Jan; 147():55-66. PubMed ID: 29106905 [TBL] [Abstract][Full Text] [Related]
9. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge? Cacciari B; Spalluto G; Federico S Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248 [TBL] [Abstract][Full Text] [Related]
10. The adenosine A Franco R; Lillo A; Navarro G; Reyes-Resina I Expert Opin Ther Targets; 2022 Sep; 26(9):791-800. PubMed ID: 36300278 [TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives. Al-Attraqchi OHA; Attimarad M; Venugopala KN; Nair A; Al-Attraqchi NHA Curr Pharm Des; 2019; 25(25):2716-2740. PubMed ID: 31333093 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of adenosine antagonist activity of a series of [1,2,4]triazolo[1,5-c]quinazolines. Balo C; López C; Brea JM; Fernández F; Caamaño O Chem Pharm Bull (Tokyo); 2007 Mar; 55(3):372-5. PubMed ID: 17329874 [TBL] [Abstract][Full Text] [Related]
13. 5-Substituted 2-benzylidene-1-tetralone analogues as A Janse van Rensburg HD; Terre'Blanche G; van der Walt MM; Legoabe LJ Bioorg Chem; 2017 Oct; 74():251-259. PubMed ID: 28881253 [TBL] [Abstract][Full Text] [Related]
14. Do caffeine and more selective adenosine A Chen JF; Schwarzschild MA Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580 [TBL] [Abstract][Full Text] [Related]
15. An update on adenosine A2A receptors as drug target in Parkinson's disease. Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives. Chandrasekaran B; Samarneh S; Jaber AMY; Kassab G; Agrawal N Curr Pharm Des; 2019; 25(25):2741-2771. PubMed ID: 31333084 [TBL] [Abstract][Full Text] [Related]
18. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. Szabó N; Kincses ZT; Vécsei L Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):441-55. PubMed ID: 21332415 [TBL] [Abstract][Full Text] [Related]
19. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Yang M; Ma C; Liu S; Shao Q; Gao W; Song B; Sun J; Xie Q; Zhang Y; Feng A; Liu Y; Hu W; Qu X Immunol Cell Biol; 2010 Feb; 88(2):165-71. PubMed ID: 19841638 [TBL] [Abstract][Full Text] [Related]